Recent updates on GLP-1 agonists: current advancements and challenges
Real-World Clinical Observations In my functional medicine practice, I've been carefully monitoring patients who begin low-dose GLP-1 therapy for various reasons, and the improvements in MCAS symptoms have been striking
Yes, Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with a BMI of 30 kg/m or higher, or 27 kg/m or higher with at least one weight-related comorbidity such as hypertension or dyslipidemia
Bring what you can well do the heavy lifting: Prescription/pharmacy records showing the generic drug, dose, and dates dispensed
Findings revealed heroin dependence reduces glutamatergic neurons in the BLA, potentially triggering neural repair during withdrawal
However, misuse or unsupervised use of peptide hormones, such as growth hormone, insulin, thyroid hormones, or erythropoietin, can cause serious side effects